Evaluation and pharmacovigilance of projects promoting cultivation and local use of Artemisia annua for malaria by Willcox, Merlin L et al.
Evaluation and pharmacovigilance of projects
promoting cultivation and local use of Artemisia
annua for malaria
Willcox et al.
Willcox et al. Malaria Journal 2011, 10:84
http://www.malariajournal.com/content/10/1/84 (11 April 2011)RESEARCH Open Access
Evaluation and pharmacovigilance of projects
promoting cultivation and local use of Artemisia
annua for malaria
Merlin L Willcox
1,2*, Shelly Burton
2,3, Rosalia Oyweka
4, Rehema Namyalo
5, Simon Challand
2,6 and Keith Lindsey
2,6
Abstract
Background: Several non-governmental organisations (NGOs) are promoting the use of Artemisia annua teas as a
home-based treatment for malaria in situations where conventional treatments are not available. There has been
controversy about the effectiveness and safety of this approach, but no pharmacovigilance studies or evaluations
have been published to date.
Method: A questionnaire about the cultivation of A. annua, treatment of patients, and side-effects observed, was
sent to partners of the NGO Anamed in Kenya and Uganda. Some of the respondents were then selected
purposively for more in-depth semi-structured interviews.
Results: Eighteen partners in Kenya and 21 in Uganda responded. 49% reported difficulties in growing the plant,
mainly due to drought. Overall about 3,000 cases of presumed malaria had been treated with A. annua teas in the
previous year, of which about 250 were in children and 54 were in women in the first trimester of pregnancy. The
commonest problem observed in children was poor compliance due to the bitter taste, which was improved by
the addition of sugar or honey. Two miscarriages were reported in pregnant patients. Only four respondents
reported side-effects in other patients, the commonest of which was vomiting. 51% of respondents had started
using A. annua tea to treat illnesses other than malaria.
Conclusions: Local cultivation and preparation of A. annua are feasible where growing conditions are appropriate.
Few adverse events were reported even in children and pregnant women. Where ACT is in short supply, it would
make sense to save it for young children, while using A. annua infusions to treat older patients who are at lower
risk. An ongoing pharmacovigilance system is needed to facilitate reporting of any adverse events.
Background
Artemisia annua has been used as a herbal medicine for
intermittent fevers since at least 340AD[1]. Artemisinin
was isolated from A. annua in 1971 and is today the
most powerful anti-malarial drug ever developed. Arte-
misinin combination therapy (ACT) is now recom-
mended by WHO as the first-line treatment for
uncomplicated malaria[2]. However, ACT remains rela-
tively expensive and is not consistently available in
many malarious areas, leading some NGOs to promote
the use of herbal preparations of A. annua. Preliminary
clinical trials suggest these can be effective even though
the artemisinin content is low[3,4].
There has been much debate about the appropriate-
ness, effectiveness and safety of such programmes[5].
Some critics believe it is too complicated to teach villa-
gers how to grow, harvest and prepare a plant for their
own use as a herbal medicine. Others fear that such prac-
tices may be ineffective and promote the spread of resis-
tance to artemisinin, as the dose of artemisinin in the tea
is lower than in tablets[6]. Conversely, some NGOs argue
that these programmes are often the only means of pro-
viding a sustainable supply of anti-malarial medicine in
remote areas, which have litt l eo rn oh e a l t h c a r ei n f r a -
structure. Furthermore, they argue that the herbal medi-
cine contains several anti-malarial compounds as well as * Correspondence: merlinwillcox@doctors.org.uk
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the development of resistance[7-10].
Since 1998 the NGO Action for Natural Medicine[11]
has distributed 1,200 A. annua “starter-kits” (containing
seeds and instructions for their use) to partners in 75
countries. In addition, Anamed key workers have run
over 100 week-long training seminars on natural medi-
cine in 20 different countries, mostly in Africa. Local
people trained by Anamed continue to run week-long
training seminars themselves. These seminars devote a
lot of attention to the cultivation and use of A. annua
and the full details are available in Anamed publications
[12,13]. The preparation recommended is an infusion of
5go fd r i e dA. annua leaf powder in 1 litre of water, to
be taken as 250 ml four times a day (for adults).
The aim of this study was to evaluate some Anamed
projects promoting the cultivation and local use of A.
annua for the treatment of malaria in East Africa. In
particular, the focus was to examine the feasibility of
setting up a pharmacovigilance system for potential
adverse effects, including in pregnant women.
Methods
A questionnaire was designed about the cultivation of A.
annua, treatment of patients with malaria and other ill-
nesses, and side-effects observed. Key partners in Kenya
and Uganda were identified by Anamed International (as
people who had previously participated in their semi-
nars), and these partners in turn identified other possible
respondents in their areas. Questionnaires were sent and
completed electronically or through the local network of
partners. Some of the respondents were then selected
purposively for conducting more in-depth semi-struc-
tured interviews and participant observation. The selec-
tion prioritised those partners who had treated the most
patients (in order to get as much information as possible
about adverse events observed) and those whom it was
feasible to visit within the time available. A local person
interpreted during the interviews when necessary,
although most respondents spoke good English.
Results
In total, about 45 partners were contacted of whom 39
responded (87% response rate) by completing a ques-
tionnaire and/or an interview, between July 2009 and
January 2011. In Kenya (Kisumu area), nine partners
were visited and interviewed (in November 2009), and a
further nine just filled out a questionnaire. In Uganda,
fourteen partners were interviewed (Kampala, Makondo
and Mbarara, July 2009, by SB; and Kasese and Bushe-
nyi, January 2011, by MW) and a further seven just
completed a questionnaire.
The demographic characteristics of the respondents
are summarised in table 1. Thirteen of the respondents
were health workers (equally split between biomedical
and traditional). The majority of the respondents were
not primarily health workers, but had pastoral roles in
their communities (as priests, teachers and NGO work-
ers) or simply as community members (farmers and
mothers). In Kenya, A. annua has been disseminated
primarily through the church network by Rural Exten-
sion for Africa’s Poor (REAP) [14,15] (Figure 1). They
had grown A. annua for an average of 3.3 years (range:
<1 year to 8 years). Ten of the respondents grew it in a
community garden, while all the others were growing it
in their home gardens. Nineteen respondents (49%)
mentioned they had had difficulty growing the plant.
The commonest reason was drought (13 respondents)
which caused the plants to die or flower too early
(Figure 2). Two respondents mentioned difficulty in get-
ting the seeds to germinate, and one mentioned that
seedlings had been killed by hailstones. She had since
developed a new system of protecting them - with a
mosquito net (Figure 3)! Those who had no problems in
cultivation tended to be more in highland areas with
good rainfall.
Table 1 Characteristics of respondents
N (%)
Sex Female 21 (54%)
Male 18 (46%)
Occupation Minister of Religion (pastor/nun) 9 (23%)
Manual worker (farmer/mother/builder) 8 (21%)
Biomedical health worker (doctor/nurse/
midwife/laboratory technician)
7 (18%)
Healer/naturopath 6 (15%)
Teacher 5 (13%)
NGO worker 2 (5%)
Other 2 (5%)
Figure 1 Pastor George Okuto (Kisumu, Kenya) has distributed
Artemisia annua plants to over 200 people in his community.
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Page 2 of 6Figure 4 shows the number of patients treated for pre-
sumed malaria by each respondent in the last year; over-
all this adds up to approximately 3,000 patients. One
respondent had not treated any patients in the previous
year because the A. annua crop had failed due to
drought. Most respondents fell into two broad cate-
gories: those using it mainly for themselves and their
family (who, therefore, had treated less than 10 patients
in the course of the year) and those who were treating
many other people in their community. The latter
included clerics, farmers, and health workers. One hea-
ler claimed she had treated three patients a day (which
adds up to >1,000 over the year). Five others said they
had treated over 100 malaria patients with A. annua in
the last year. The vast majority said they gave the infu-
sion for seven days, although three gave less (2-5 days)
and one gave more (up to 10 days). One respondent
used the infusion in combination with sulphadoxine-
pyrimethamine (SP), but all others used it alone for the
treatment of presumed malaria.
25 of the respondents (64%) said they had treated chil-
dren under the age of five years with A. annua tea. Most
had only treated small numbers (usually their own chil-
dren) but four respondents had treated over 30 children
in the past year with A. annua infusion; overall the num-
ber of children treated was at least 250. Most of these
lived in fairly remote communities with no health centre.
They reported that all of the children treated had recov-
ered completely (although there was no formal system
for follow-up). Three respondents mentioned that the
bitter taste affects compliance, and eight reported that
they mix the infusion with sugar or honey to improve the
taste. Two respondents mentioned that the infusion
seemed to be less effective in children, with a higher
relapse rate (one mentioned that all the children under
the age of three years had had a recrudescence). Only
one respondent mentioned a rash in one child after tak-
ing the infusion, which settled after four days, while he
was still taking the infusion. He had taken the infusion
many times previously with no problems. No other
adverse events were reported in children.
Figure 2 Ester Odhiambo (Rusinga Island, Kenya) demonstrates
poor growth of Artemisia annua due to drought.
Figure 3 Monica Khagoni (Ingidi, Kenya) with her mosquito-net
shelter to protect Artemisia annua seedlings from hailstones.
Figure 4 Number of patients treated for presumed malaria
with Artemisia annua infusion in the last year by each
respondent.
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first trimester of pregnancy with A. annua tea, and
reported on a total of at least 54 patients. Two miscar-
ried, one reported severe vomiting and one reported
joint pains, weakness and pruritus. The other 50 women
were reported to have had no adverse effects, and
indeed most had already delivered a healthy baby (a few
had not yet delivered). One doctor had conducted a
“trial” of Artemisia tea for 20 women in the first trime-
ster of pregnancy, and found that the remedy was better
tolerated than quinine, so that he felt compliance and
outcomes were better. He had followed up the pregnant
women carefully with blood tests and ultrasound scans
until their delivery, and all had delivered normal babies.
He observed that some of the women continued taking
the tea (against his advice) throughout their pregnancy
as a prophylactic.
Although the questions focussed on the first trimester,
five respondents mentioned that they had treated a total
of nine pregnant women in their second trimester (in
two cases they had treated themselves while pregnant).
None of these had had any problems. Two respondents
mentioned that women had started taking A. annua tea
as a form of emergency contraception, or to induce
abortion within one month of conception.
Apart from young children and pregnant women, only
four respondents had observed adverse events in other
patients. These were vomiting (three respondents), prur-
itus, rashes, diarrhoea and headache (each mentioned by
one respondent). One respondent who was particularly
careful about following up her patients (n = 17 over the
last year) reported that about 20% reported a side-effect
(one or more of vomiting, diarrhoea, rash).
Respondents were asked whether they had noticed the
tea becoming less effective since they had started using
it. Only five reported that they had, in a few patients, or
that they now gave a longer treatment (ten days instead
of seven).
Twenty respondents (51%) also mentioned that they
had started using A. annua to treat illnesses other than
malaria. These included: gastrointestinal conditions
(pain/diarrhoea/typhoid/intestinal parasites - in 11
respondents), HIV/AIDS (11), haemorrhoids (5), cough
(5), skin conditions (3), amenorrhoea (2), as a contra-
ceptive (2), as an insect repellent (2), and various other
miscellaneous uses.
Discussion
Although many NGO projects promote the cultivation
and local use of Artemisia annua,t h i si st h ef i r s tp u b -
lished evaluation of such a project. Although only a
small sample of partners was interviewed, it is clear that
local small-scale cultivation and preparation of A. annua
are feasible in East Africa, within the context of broader
development projects promoting self-reliance[14]. The
church seems to have a better infrastructure than the
formal health system, particularly in remote areas, and
can reach communities which have no health services.
The main practical problem was that cultivation was
adversely affected by droughts in several areas. In
drought-prone areas, drought-resistant anti-malarial
plants such as Argemone mexicana w o u l db em o r es u i -
table[16-18]. Artemisia annua is more suited to high-
land areas with better rainfall.
One important caveat to this study is that it was retro-
spective, and it was not possible to test the patients to
confirm whether they actually had malaria, or another
cause for their symptoms. Nevertheless the areas
selected have high transmission of malaria so it is rea-
sonable to assume that a significant proportion of the
cases reported did actually have malaria. Furthermore,
the authors relied on the honesty of the respondents in
reporting adverse events as they did not have the
resources to track individual patients. Of course it is
probable that not all adverse events were reported by
patients to those who had treated them. This is a flaw
inherent in almost all pharmacovigilance systems.
Although clinical trials of A. annua have all excluded
children [5], almost two-thirds of respondents had used
the infusion to treat malaria in young children (age <5
years) who are at greatest risk of severe malaria and death.
The main problem observed was compliance, which can
be improved by adding sugar or honey. Some had
observed a higher relapse rate in young children. However
in a situation where no other treatments are available, the
infusion is probably better than nothing. Nevertheless clin-
ical trials are needed to see whether the infusion can really
be recommended for the treatment of young children.
Although ACT is now provided free of charge in gov-
ernment health facilities in many African countries,
r e c e n ts t u d i e ss h o wt h a ti tw a so u to fs t o c kf o r2 0 %o f
the time in Kenya[19], and for 30% of patients in
Uganda[20]. Interviews suggested that availability was
even more limited than this in some areas. When health
facilities had run out of ACT, Anamed partners were
sometimes the only source of anti-malarial treatment in
their community. In this situation of insufficient supply
of ACT, it would make sense to save ACT for young
children, while using A. annua infusions to treat older
patients who are at lower risk (in high-transmission
areas where residents develop partial immunity). The
herbal infusion can also be combined with another anti-
malarial drug which may be more readily available than
an ACT. This practice was reported by two respondents:
one only ever gave the infusion in combination with SP
while another (a nurse) added SP in cases with high
parasitaemia. All other respondents said they used A.
annua infusion alone for the treatment of malaria.
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is generally not recommended because of animal studies
which have shown a potential to induce foetal resorp-
tion[21]. Artemisinin is generally considered to be safe
in the second and third trimesters of pregnancy and
now artesunate is recommended as the first line treat-
ment for pregnant women with severe malaria[2].
Although Anamed does not recommend use of A.
annua in the first trimester of pregnancy[12], sometimes
this happens accidentally when a woman does not rea-
lize she is pregnant. On other occasions, A. annua tea
may be given when no other treatments are available.
Although some cases of miscarriage were reported after
use of the plant, the incidence was relatively low (2/54 =
3.7%, 95% CI 0.5 - 12.7%) and is probably not greater
than the background incidence in the population. This
seems lower than the 20% miscarriage rate observed in
16 pregnant women who had taken artesunate in the
first trimester[22] although the difference is not statisti-
c a l l ys i g n i f i c a n t( p=0 . 1 3 ) .I ti sp o s s i b l et h a tt h e r em a y
have been under-reporting of miscarriage in the first tri-
mester. Very early miscarriages may not be viewed as
abnormal or worth reporting. In Kenya abortion is ille-
gal; one respondent was anxious that if it was found out
t h a ts o m eo fh i sp a t i e n t sh a dm i s c a r r i e d ,h em i g h tb e
accused of procuring abortions. This fear may have
deterred others from reporting miscarriages.
It was generally widely accepted that the infusion was
well tolerated with few side-effects. Most of the “side-
effects” reported could equally have been symptoms of
malaria. For example it is difficult to determine whether
nausea/vomiting was caused by the disease or the treat-
ment. A randomised controlled trial has shown that A.
annua infusion is better tolerated than quinine[4].
Nevertheless it is good practice to have a system of
pharmacovigilance for any treatment, therefore we left
forms with project partners to encourage them to report
in detail any adverse events observed. These can be fed
back via local networks (for example REAP) to Anamed.
From now on Anamed will send feedback and pharma-
covigilance forms to its partners one year after providing
a “starter pack”, to improve reporting of any adverse
events. Setting up pharmacovigilance systems is also a
challenge for biomedical treatments [23].
It is difficult to design a study to show whether use of
Artemisia tea will promote resistance to artemisinin.
There are arguments on both sides, but no proofs[5].
Although respondents had not been using the plant for
very long, five reported that they thought it was becom-
ing less effective. It would be interesting to examine this
in more detail as there could be many causes. It is unli-
kely that the parasite would have evolved resistance to
artemisinin over such a short period of time. A possible
explanation is that high artemisinin yields in the standard
hybrid plants will diminish in following generations if the
plants are propagated by seeds rather than by vegetative
means. Although Anamed promotes vegetative propaga-
tion (and this was practiced by many partners) some
respondents did mention that the plants seed themselves,
and they use the next generation of plants also. Even
when using vegetative propagation as recommended, it
has been found that artemisinin yields in some parts of
East Africa are 0.20-0.35% (compared to the ideal of
>1%)[24]. This may be due to different climatic condi-
tions and lower altitude. In particular dry conditions will
cause early flowering, which will reduce the yield of arte-
misinin (which is maximal just before flowering). For this
reason it is important to develop a practical field method
for quality control of A. annua plants.
Another interesting observation was that partners
were using A. annua as a treatment for conditions other
than malaria, especially diarrhoea/abdominal pain and
HIV/AIDS. It is not impossible that the remedy is useful
in these situations. Anamed has received informal feed-
back from many partners that they find A. annua,i n
combination with Moringa oleifera leaf powder, to be a
useful supportive treatment in patients with HIV/AIDS
[25]. Artemisinin has some antiviral activity against HIV
itself and against opportunistic infections such as cyto-
megalovirus and herpes viruses[26]. Artemisia annua
infusion has been shown to be active against faecal
micro-organisms [27] and schistosomiasis[28], and also
has an immunostimulatory effect on phagocytes in a
mouse model[29]. Further research is needed to explore
these possible beneficial effects.
Conclusions
Local cultivation and preparation of A. annua are feasible
where growing conditions are appropriate. Other plants
may be better suited to drought-prone areas. Few adverse
events were reported even in children and pregnant women,
although further research is needed before deciding whether
use of the remedy can be promoted in these groups. Mean-
while where ACT is in short supply, it would make sense to
save it for young children, while using A. annua infusions to
treat older patients who are at lower risk. A pharmacovigi-
lance system is being set up to encourage reporting of any
adverse events. Artemisia annua tea is also being used to
treat other conditions, but further research is needed to
determine whether it is effective for these.
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